Stability Studies

From protocol to reporting, our stability studies support confident shelf‑life assignment.

Drug Manufacturing banner

Shelf‑life supported by stability data

Long-term and accelerated stability programs designed to produce regulatory‑ready data.

Stability studies demonstrate how a drug product’s quality changes over time under defined environmental and physical conditions, generating the evidence used to support shelf life and storage expectations.

At Groupe PARIMA, stability testing is performed in-house and is integrated with long-term and accelerated stability activities within formulation development, scale-up, and commercial manufacturing.

Stability Conditions
by Target Market

We run ICH‑aligned standard conditions, plus cold‑chain and specialized studies, to match your product’s storage, distribution, and target markets.

Card 01

Long‑Term

25°C / 60% RH long‑term studies generate the core data package used to support shelf life and labeled storage conditions for temperate markets.

Card 02

Intermediate

30 °C / 65% RH intermediate studies are conducted only if a significant change occurs at accelerated conditions, to provide reliable support for shelf‑life.

Card 03

Zone IV‑B

30°C / 75% RH supports programs intended for hot/high‑humidity regions, defined as a long‑term condition.

Card 04

Accelerated

40°C / 75% RH accelerated studies help characterize stability trends earlier and support risk‑based decisions during development and registration planning.

Card 05

Cold‑Chain

Cold condition studies (2–8 °C) demonstrate stability for products intended for refrigerated storage, where higher temperatures would accelerate degradation without reflecting actual use conditions.

Card 06

Frozen Conditions

−20°C conditions are available for highly sensitive products requiring frozen storage, to prevent degradation or maintain stability that cannot be achieved at higher temperatures.

Stability studies at Groupe PARIMA support confident shelf‑life decisions through controlled, specification‑driven testing across defined storage conditions.

Resources

Access stability insights and guidance to support shelf‑life, storage conditions, and lifecycle decisions.

Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development
Groupe PARIMA
2026/04/27
How Drug Product Formulation Works: Topical, Oral, and Nasal Liquid and Semi-Solid Dosage Forms
Groupe PARIMA
2026/03/18
How Early API Characterization Can Reduce Formulation and Scale-up Risks
Groupe PARIMA
2025/10/23
Topical 101: A Guide to Complex Dermatology Formulation Development

Contact us

Stability test you can trust.

Let’s review your stability protocol, target markets, and packaging to generate regulatory‑ready data across defined storage conditions.